Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum levels of tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy

Canadian Journal of Gastroenterology and Hepatology

Volumn 28, Issue 1, 2014, Pages 35-40

  Cooper, Curtis ^a   Shafran, Stephen ^b   Greenbloom, Susan ^c   Enns, Robert ^d   Farley, John ^e   Hilzenrat, Nir ^f   Williams, Kurt ^g   Elkashab, Magdy ^h   Abadir, Nabil ⁱ   Neuman, Manuela ^j  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Toronto Digestive Disease Associates   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Private Practice   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g ROYAL UNIVERSITY HOSPITAL   (Canada)

^h Private Practice   (Canada)

ⁱ Merck Canada Inc   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

HCV; Infliximab; Interferon; TNF alpha; Viral kinetics

Indexed keywords

INFLIXIMAB; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANADA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HYPOTHESIS; LIVER FIBROSIS; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CANADA; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 84904250191     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2014/367131     Document Type: Article

References (17)

1. Koziel MJ, Dudley D, Afdhal N, et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993;67:7522-32. (Pubitemid 23343882)
2. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem 2001;34:167-71. (Pubitemid 32537667)
3. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999;19:157-69.
4. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-74.
5. Neuman MG, Benhamou JP, Martinot M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999;32:537-45. (Pubitemid 30007764)
6. Neuman MG, Benhamou JP, Bourliere M, et al. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 2002;17:108-17.
7. Neuman MG, Benhamou JP, Malkiewicz IM, et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001;34:173-82. (Pubitemid 32537668)
8. Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996;16:390-9. (Pubitemid 27042775)
9. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996;23:210-7. (Pubitemid 26045936)
10. Neuman MG, Benhamou JP, Malkiewicz IM, et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002;9:134-40. (Pubitemid 36002477)
11. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256-65. (Pubitemid 37040219)
12. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994;179:841-8. (Pubitemid 24065641)
13. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: A systematic review. Rheumatology (Oxford) 2011;50:1700-11.
14. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82. (Pubitemid 37323572)
15. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22. (Pubitemid 40254244)
16. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
17. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: A retrospective record review of 11 patients. Clin Rheumatol 2009;28:787-91.